Clinical trial
Elranatamab, Lenalidomide, Dexamethasone in Newly Diagnosed Multiple Myeloma, a Clinical and Correlative Phase 2 Study
NCT06997081 is registered in ClinicalTrials.gov with University of Miami as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Elranatamab, Lenalidomide, Dexamethasone in Newly Diagnosed Multiple Myeloma, a Clinical and Correlative Phase 2 Study
- Lead sponsor
- University of Miami
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- September 16, 2025
- Completion date
- September 30, 2030
- Enrollment
- 104 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.